TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.

NCT00744809 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Volunteers

Interventions

DRUG: TMC278; Moxifloxacin; Efavirenz

Sponsor

Tibotec Pharmaceuticals, Ireland